




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification n 6: A61N 1/05		A1	(11) International Publication Number: WO 99/65561
		(43) International Publication Date: 23 December 1999 (23.12.99)	
(21) International Application Number: PCT/US99/13719		(81) Designated States: CA, DE, FI, GB, JP, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(22) International Filing Date: 17 June 1999 (17.06.99)		Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(30) Priority Data: 60/090,009 19 June 1998 (19.06.98) US 60/110,054 25 November 1998 (25.11.98) US			
(71) Applicant: CORDIS WEBSTER, INC. [US/US]; 3333 Diamond Canyon Road, Diamond Bar, CA 91765 (US).			
(71)(72) Applicants and Inventors: SCHERLAG, Benjamin, J. [US/US]; 11403 Spring Hollow Road #207, Oklahoma City, OK 73120 (US). SCHERLAG, Michael [US/US]; 7304 N.W. 111th Terrance, Oklahoma City, OK 73162 (US). SCHAUERTE, Patrick [US/US]; Chevy Chase Apartments, 6490 N. Warren #279, Oklahoma City, OK 73116 (US).			
(72) Inventor: WEBSTER, Wilton, W., Jr.; 3333 Diamond Canyon Road, Diamond Bar, CA 91765 (US).			
(74) Agent: DILLARD, David, A.; Christie, Parker & Hale, LLP, P.O. Box 7068, Pasadena, CA 91109-7068 (US).			

(54) Title: METHOD AND APPARATUS FOR TRANSVASCULAR TREATMENT OF TACHYCARDIA AND FIBRILLATION



(57) Abstract

The present invention provides a method of controlling cardiac fibrillation, tachycardia, or cardiac arrhythmia by the use of an electrophysiology catheter (10) having a tip section (12) that contains at least one stimulating electrode (14, 16), the electrode being stably placed at a selected intravascular location. The electrode is connected to a stimulating means (18). Stimulation is applied across the wall of the vessel, trans-vascularly, to a sympathetic or parasympathetic nerve that innervates the heart at a strength sufficient to depolarize the nerve, and effect the control of the heart.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

METHOD AND APPARATUS FOR TRANSVASCULAR TREATMENT OF TACHYCARDIA AND FIBRILLATION

BACKGROUND OF THE INVENTION

The field of the invention is the control of tachycardia, including fibrillation, and arrhythmias, particularly the control of atrial fibrillation and ventricular tachycardia.

Tachycardia is the rapid beating of the heart, caused by abnormalities in any part of the heart, for example the atria, Purkinje system, or ventricles. Often, the extremely rapid beating of the heart is uncoordinated, and leads to fibrillation or flutter. These conditions occur after myocardial infarctions, for example, or in various pathological conditions, such as a dilated heart, blockage of the Purkinje system, or following chemical therapies (e.g., epinephrine) or repetitive stimulation. Atrial flutter often becomes atrial fibrillation within a few days or weeks, and leads to a complete failure of the atria to pump blood.

Atrial fibrillation is the most frequent tachycardia in patients. It most frequently occurs in patients over the age of 60 years, and affects over 8% of patients with cardiovascular disease and people older than 80 years (1, 2). Chronic atrial fibrillation doubles mortality (3), mostly due to an increased risk of stroke as well as other cardiovascular complications. Among other risk factors, congestive heart disease imposes the highest risk for developing atrial fibrillation (4.5-5.9 fold) (4). Therefore, restoration of normal sinus rhythm by pharmacological or electrical cardioversion is attempted in many patients with atrial fibrillation. Unfortunately, atrial fibrillation recurrence rates one year after successful cardioversion are high (75% without antiarrhythmic drug prophylaxis and 50% with aggressive antiarrhythmic medication; (5)). Moreover, the likelihood of cardioversion success is low in patients with chronic atrial fibrillation lasting longer than 2 years or who have enlarged atria (6). In many of these patients, therapy is directed toward ventricular rate control during atrial fibrillation in order to stabilize cardiac function. However, in patients with concomitant heart failure, drugs that slow the ventricular rate during atrial fibrillation may further depress ventricular contractility and cause arterial hypotension or be of limited use due to side effects.

Like atrial fibrillation, ventricular tachycardia can lead to fibrillation, which leads to failure of the ventricles to pump blood. Unlike atrial fibrillation, ventricular fibrillation cannot be compensated for by the rest of the heart and rapidly leads to sudden death if not reversed. Ventricular fibrillation is a common cause of death in patients (7). For example, patients who survive myocardial infarction often remain at risk for reentrant ventricular tachycardia. The sympathetic and parasympathetic nerves (autonomic innervation) of the heart influence susceptibility to spontaneous arrhythmias. Sympathetic stimulation can increase the risk of fatal arrhythmias during ischemic events and parasympathetic stimulation can decrease the risk (8). Current efforts to control this excess sympathetic tone include administration of β -adrenergic blocking drugs and surgical sympathectomy (9). Problems with these methods

1 include contraindications for drug therapy in patients who are sensitive to the negative inotropic effects of β -adrenergic blockade and the inherent risks of thoracic surgery, which in this case also include pulmonary complications, injury to the brachial plexus, and upper extremity paresthesias.

5 Another common measure used to control atrial or ventricular tachycardia is ablation or modification of the His bundle or atrioventricular node and ablation of atrial or ventricular foci. Such ablation may abolish a tachycardia or slow the ventricular response during atrial fibrillation by blocking impulse conduction across the atrioventricular node. Ablation can be performed by introduction of a catheter into the heart through the venous system and subsequent ablation of
10 the tissue.

In 1973, Lazzara and Scherlag reported that electrical stimulation of parasympathetic cardiac nerves at the junction of the right atrium and the inferior vena cava close to the coronary sinus ostium selectively prolonged atrio-ventricular (AV) conduction time (10). Chen *et al.* showed control of ventricular rate during atrial fibrillation by short bursts of stimulation to
15 parasympathetic nerves in the fat pads to the AV node, but this method can lead to unwanted stimulation of myocardial muscle, and stimulation times are necessarily very brief because the electrode cannot be stably maintained in the appropriate location. Most recently, Reek *et al.* (12) reported that stimulation of the parasympathetic nerve fibers in the RPA with a conventional electrode catheter decreased the sinus rate in sheep. In addition, electrical stimulation of
20 parasympathetic nerves either during coronary artery bypass grafting operation (CABG) (13) or after CABG operation (14) have demonstrated that parasympathetic fibers innervating the sinus and atrioventricular node can also be stimulated in humans. The stimulation electrodes, however, were only temporarily fixed at the outer surface of the heart or superior vena cava. Chiou *et al.* demonstrated that extracardiac electrical stimulation of parasympathetic fibers in fat
25 pad between the superior vena cava, the aorta, and adjacent to the right pulmonary artery, diminished AV nodal conduction during sinus rhythm (15). These results required a thoracotomy. Most recently, Thompson and coworker reported that endovascular electrical stimulation of parasympathetic fibers in the superior vena cava with a conventional electrode catheter slows the sinus rate (16).
30

SUMMARY OF THE INVENTION

The present invention provides a method and system for controlling the heart rate of a patient and is particularly useful in controlling cardiac fibrillation and tachycardia. The method
35 involves the intravascular stimulation and/or ablation of cardiac parasympathetic and sympathetic nerves sufficient to regulate or slow the heart rate or prevent the occurrence of these arrhythmias.

The method comprises providing an electrophysiology catheter comprising at least one

1 electrode and preferably an electrode array, e.g., in an expandable electrode basket, at its distal
end. The catheter is inserted into a blood vessel and directed to a location wherein the electrode
through which a stimulus is delivered is adjacent to one or more predetermined cardiac
parasympathetic or sympathetic nerves. A selected stimulus preferably a pulsed electrical signal,
5 is then delivered through the electrode(s) to slow or regulate the beating rate of the heart. The
stimulus is maintained for an extended period to provide a physician sufficient time to administer
a drug, operate or take other appropriate measures to attempt to permanently or at least more
permanently establish normal heart rhythm or slow the heart rate. Such a period may require
several hours.

10 The selected stimulus is preferably below the threshold needed to depolarize the cardiac
muscle or it is applied sufficiently far from the cardiac muscle so that depolarization does not
occur. Alternatively, a stronger stimulus intensity may be used if it is timed to occur during
the myocardial refractory period. The refractory period can be induced at regular intervals
by pacing the contraction of the myocardium with electrical pulses applied from the same or
15 a different electrode as is used to apply the nerve stimulation.

A preferred stimulus for stimulating a predetermined parasympathetic nerve is a pulsed
electrical signal having a frequency of from about 1 to about 200 Hz, preferably about 20 -
30 Hz, having an intensity or strength of from about 1 to about 200 volts as measured at the
electrodes tissue interface, preferably from about 8 to about 15 volts. The duration of each
20 stimulating pulse is from about 1 microsecond to about 10 milliseconds, preferably from about
50 μ sec (0.05 ms) to about 600 μ sec (0.6 ms), most preferably from about 50 μ sec to about
100 μ sec.

It is understood that the frequency, intensity and duration of the signal may vary. For
example, depending on the precise location of the electrode through which a stimulus is
25 delivered and the nerve to be stimulated, a signal of greater or lesser strength may be
required. In such a situation, the stimulus can be varied during the procedure until the desired
slowing of the heart rate is achieved. That is, if no response is achieved initially, the voltage
may be increased in steps, e.g., of 5-10 volts/step until a response is seen. Likewise, the
frequency, pulse duration and polarity may be adjusted. Clearly, other parameters may be
30 varied including the location of the electrode to achieve and/or improve the response.

It is further understood that the stimulating signal may be of sufficient intensity,
frequency and duration to ablate the nerve. This is done, for example, if a patient is at high
risk of ventricular tachycardia from cardiac sympathetic stimulation, common after myocardial
infarction, where the patient has vagally maintained atrial fibrillation (17). Stimulation
35 frequencies in the radiofrequency range (e.g., over 10 kHz) can be used for ablation.
Alternatively, ablation may be achieved by any other suitable means, for example any thermal
means or cryoablation means.

Preferred intravascular sites for stimulation of parasympathetic nerves include the right

1 pulmonary artery, the superior vena cava, and the coronary sinus. Stimulation at these sites
is useful to control a variety of arrhythmias and tachycardias, including atrial fibrillation and
ventricular tachycardia.

5 The system comprises a catheter, preferably a steerable catheter having a tip section
containing one or more electrodes. The catheter may be any type that can be safely placed
and maintained in a desired location in a blood vessel without unduly impeding blood flow.
A preferred catheter for use in the invention has a variably expandable electrode section, most
preferably a basket catheter having a basket assembly at the catheter's distal end. The basket
10 assembly comprises a plurality of splines connected at their proximal and distal ends, at least
one and preferably all splines comprising at least one electrode. The basket assembly is
movable between a collapsed arrangement and an expanded, "bowed-out" arrangement.
Preferably, the basket assembly, in its expanded arrangement, has a length of from about 2
cm to about 6 cm, preferably from about 2 to about 4 cm and a diameter of from about 10
15 to about 30 mm, preferably about 10 to about 20 mm. The splines of the basket catheter may
carry one or more electrodes or may form electrodes themselves. In a preferred embodiment,
each spline has an uninsulated central section which can serve as an electrode and one or more
ring or wrapped electrodes on the insulated end portions of the spline. The basket
arrangement allows very precise and stable localization of stimulation.

20 The system further comprises a low frequency pulsed signal generator electrically
connected to the stimulating electrode for generating a stimulating signal, a monitor and/or
display for recording and/or displaying the patient's heartbeat rate and one or more indifferent
electrodes. In a particularly preferred embodiment of the invention, the system further
comprises a programmable controller which is electrically connected to the pulse generator
25 and to a sensor which senses the heartbeat rate of the patient. The controller, when activated,
is programmed to stimulate each electrode of the electrode array to determine which is closest
to the nerve and to vary, preferably in a stepwise fashion, one or more of the intensity,
frequency or pulse duration of the stimulating signal to achieve the desired lowering of the
heartbeat rate.

30 The present invention avoids the disadvantages of previous therapies. It provides a
consistent and stable means for transvascular electrical stimulation and/or ablation
(denervation) that affects cardiac parasympathetic and sympathetic nerves, effecting a decrease
in the rapid atrial and ventricular responses during atrial fibrillation and other tachycardias
without affecting ventricular contractility. The invention's transvenous approach to
parasympathetic or sympathetic nerves offers an improved opportunity for acute and chronic
35 ventricular rate control during atrial or ventricular tachycardia or fibrillation and other
arrhythmias without concurrent stimulation of the heart muscle itself, and without the use of
contraindicated drugs. Unlike previous intravascular stimulation efforts, the expandable or
basket catheter of the invention allows long term, stable placement of the electrode for

1 accurate, repeatable stimulation at the desired location. Additionally, the short pulse duration
reduces the risk of unwanted myocardial stimulation.

DESCRIPTION OF THE DRAWINGS

5 These and other features and advantages of the present invention will be better
understood by reference to the following detailed description when considered in conjunction
with the accompanying drawings wherein:

10 FIG. 1: A schematic of a preferred system for regulating the heart rate of a patient.

FIG. 2A: Enlarged view of the distal end of the catheter of the system shown in
Fig. 1.

FIG. 2B: Enlarged view of the distal end of a preferred catheter used for ablation,
having splines uninsulated along their entire length.

15 FIG. 3: Illustration of the influence of the frequency of cardiac nerve stimuli on the
supraventricular rate slowing effect. In this dog, nerve stimulation was applied in the superior
vena cava with an impulse duration of ____ ms and an intensity of 26 V. At a frequency of
20 Hz, the effect reached a plateau until it decreased at a frequency of 45 Hz.

20 FIG. 4: Cardiac nerve stimulation (PS) in the coronary sinus (CS). Surface ECG
lead II, aVR and a right atrial appendage (RAA) recording are depicted. Atrial fibrillation
was induced and maintained by rapid pacing from the RAA at a cycle length of 100 ms (low
frequency, low amplitude pacing artifacts on the right of the RAA-tracing). PS was done at
25 a stimulus strength of 34 V and a frequency of 20 Hz (high frequency, high amplitude
electrical artifacts can be seen on the left of the RAA-tracing). The cycle length values within
the figure refer to the longest and shortest R-R interval during AF with PS (1976 and
1440 ms, respectively) and when PS was terminated (arrow, 600 and 260 ms, respectively).

30 FIG. 5: Effect of stimulus strength (SST) on ventricular rate slowing during cardiac
nerve stimulation (PS) in the coronary sinus. The average R-R interval during atrial
fibrillation (AF) is plotted versus the SST. The SST significantly affected the R-R interval
during AF ($p < 0.001$, ANOVA). The mean R-R interval at each SST was also compared to
the R-R interval without PS ($*p < 0.05$). Of note, during epicardial PS the threshold for a
35 ventricular slowing effect during AF was considerably lower than during intravascular PS.

FIG. 6: Cardiac nerve stimulation in the right pulmonary artery. Surface ECG leads
II and aVR are depicted. The offset of nerve stimulation is indicated by the vertical arrow.

1 The electrical artifacts of cardiac nerve stimulation can be seen as higher voltage, high
frequency signals on the left in the ECG tracings. The smaller pacing artifacts (cycle length
100 ms) for the induction and maintenance of atrial fibrillation (AF) are hidden by the nerve
stimulation artifacts but can be seen after cessation of cardiac nerve stimulation (arrow). At
5 a cardiac nerve stimulus intensity of 27 V (stimulus frequency: 20 Hz, stimulus duration: 0.05
ms) atrio-ventricular conduction during atrial fibrillation was substantially prolonged resulting
in marked ventricular pauses (longest 3016 ms, shortest 2008 ms). After nerve stimulation was
terminated, a rapid ventricular response (longest: 672 ms, shortest: 452 ms) resumed almost
immediately.

10 FIG 7: Effect of stimulus strength (SST) on ventricular rate slowing during cardiac
nerve stimulation (PS) in the right pulmonary artery (RPA). The average ventricular rate
interval (R-R interval) during atrial fibrillation (AF) is shown on the ordinate whereas the
abscissa represents the SST. With increasing SST the R-R interval during AF was lengthened
15 ($p < 0.001$, ANOVA). Individual values of the R-R interval at each SST were compared to the
R-R interval without PS ($*p < 0.05$).

FIG. 8A: Cardiac nerve stimulation in the superior vena cava (SVC). Surface ECG
leads I, II and a VF and a recording of the stimuli (stim) delivered to the basket catheter are
20 depicted. Atrial fibrillation was induced and maintained by rapid pacing from the RAA at a
cycle length of 100 ms (low frequency, low amplitude electrical artifacts). The onset of
parasympathetic nerve stimulation (PS) is indicated by a vertical arrow. At a PS intensity of
13 V (stimulus frequency of 20 Hz, the shortest R-R interval during atrial fibrillation
prolonged from 352 ms to 384 ms and the longest R-R interval from 408 to 1464 ms.

25 FIG. 8B: Increasing the stimulus amplitude to 27 V led to an even greater increase of
the R-R intervals (shortest: 272 ms to 1008 ms; longest: 380 ms to 2336 ms). The onset of
parasympathetic stimulation is indicated by vertical arrow.

30 FIG. 9: Effect of stimulus strength (SST) on ventricular rate slowing during cardiac
nerve stimulation (PS) in the superior vena cava (SVC). The average ventricular rate interval
(R-R interval) during atrial fibrillation (AF) is shown on the ordinate whereas the abscissa
represents the SST. A substantial prolongation of the R-R interval with increasing SST was
observed ($p < 0.001$, ANOVA). Individual values of the R-R interval at each SST were
35 compared to the R-R interval without PS ($*P < 0.05$).

FIG. 10A: Effect of intermittent cardiac nerve stimulation on atrioventricular
conduction during atrial fibrillation. Surface ECG lead II and aVR and an epicardial recording

1 from the right atrial appendage (RAA) are shown. Trains of 200 Hz stimuli, each lasting 10
ms were delivered at a train rate of 200/min. These trains can be seen as large regular
electrical artifacts in the right atrial appendage (RAA) recording. atrial fibrillation (AF) was
5 induced and maintained with rapid atrial pacing (cycle length 100 ms, high frequency, low
amplitude pacing artifacts in the RAA recording). The onset of nerve stimulation is indicated
by a horizontal arrow in the RAA tracing. At a stimulus strength of 34 V, intermittent,
regular nerve stimulation markedly reduced the ventricular response during atrial fibrillation
(longest R-R = 1784 ms; shortest R-R = 1120 ms).

10 FIG. 10B: This negative dromotropic effect depended on the train rate. At the
beginning, trains were delivered at a shorter but irregular cycle length (frequent pulsing)
resulting in a notable ventricular rate slowing during atrial fibrillation (longest R-R = 1900
ms; shortest R-R = 630 ms). When the pulsing rate became infrequent and irregular (right side
of the recording), the ventricular rate slowing effect during atrial fibrillation was considerably
15 less (longest R-R = 600 ms; shortest R-R = 265 ms).

FIG. 11: Continuous parasympathetic cardiac nerve stimulation in the coronary sinus
over 20.5 hours. The ventricular rate (R-R interval) during atrial fibrillation (AF) is plotted
versus time. After a slight decrease of the rate slowing effect during the initial 2 hours the rate
20 slowing effect persisted over the remaining 20.5 hours. There was always a reserve of the
negative dromotropic effect as demonstrated by a further prolongation of the R-R interval
when the stimulus voltage was intermittently increased from 25 to 39 V.

25 DETAILED DESCRIPTION OF THE INVENTION

The present invention provides a system comprising a minimally invasive catheter and
low frequency pulsed signal generator for treating and preventing atrial and ventricular
tachycardia and cardiac arrhythmias by specific stimulation of parasympathetic or sympathetic
nerves innervating the heart. The invention also provides a system comprising a minimally
30 invasive catheter and an ablation signal generator for treating and preventing tachycardia by
specific ablation of parasympathetic and/or sympathetic nerves innervating the heart. As used
herein, "tachycardia" means the rapid beating of the heart, and can include fibrillation and
flutter. "Fibrillation" means an uncoordinated contraction of cardiac muscle, leading to
inefficient pumping of the heart. "Flutter" means an extremely rapid beating.

35 A preferred system in accordance with the present invention is shown in Figs. 1 and
2. The system comprises a steerable catheter 10, having an expandable basket assembly 12
at its distal end. The basket assembly 12 carries a plurality of electrodes 14 and 16 which are
electrically connected to a signal generator 18 by electrode lead wires (not shown) which

1 extend through the interior of the catheter and electrical connection 19. One or more
indifferent electrodes 20 which are placed on the patient's skin are also electrically connected
to the signal generator 18 by electrical connection 21.

5 The signal generator 18 is capable of generating a signal having a frequency from about
1 to about 20 Hz, preferably about 20 to about 30 Hz and having an intensity of from about
1 to about 150 volts, preferably from about 8 to about 15 volts and a pulse duration of from
about 1 microsecond to about 10 milliseconds, preferably from about 50 to about 600
microseconds.

10 One or more sensors 22 are provided for monitoring the heartbeat of the patient. The
sensors are electrically connected via line 23 to a recorder/display 24 for recording and/or
displaying the patient's heartbeat, preferably in the form of a conventional electrocardiogram
or the like. In the embodiment shown, a programmable controller 26 is electrically connected
to the signal generator 18 via line 25 and to sensors 22, e.g., via line 27 to recorder/display
24.

15 The catheter 10 comprises an elongated tubular catheter body 30, a tip section 32 at the
distal end of the catheter body 30 and a control handle 34 at the proximal end of the catheter
body 30. The catheter body 30 comprises an elongated tubular construction having a single,
central or axial lumen. The catheter body 30 is flexible, i.e., bendable, but substantially non-
compressible along its length. The catheter body 30 preferably comprises a tubular wall of
20 high-strength braided stainless steel or other high-strength wire or fiber, sandwiched between
inner and outer layers of firm, yet flexible, polyurethane. This high torque shaft structure
allows a physician to control the orientation of the electrode basket by rotating the catheter
body 30 where it enters the patient's body, which is usually at the groin or neck. The catheter
body 30 preferably further comprises a nylon stiffening sleeve lining the interior of the tubular
25 wall. A suitable construction of the catheter body is disclosed in U.S. Patent No. 5,827,278
which is incorporated herein by reference. The outer diameter of the catheter body 30 is not
critical but is preferably no more than about 8 French and more preferably no more than
about 7 French. Likewise, the thickness of the outer wall is not critical.

30 The catheter tip section 32 comprises a short section of flexible tubing preferably
having a diameter of about 6-7 French, and having a pair of off axis lumens. At the distal
end of the tubing of the tip section, there is provided an expandable basket assembly 36. A
preferred basket assembly construction is disclosed in U.S. Patent No. 5,772,590, which is
incorporated herein by reference. In such a construction, the basket assembly has five arms
and a central puller wire. The arms are fixed at their proximal ends to a proximal fitting and
35 also fixed at their distal ends to a distal fitting. The proximal fitting which has a central
opening, is received by and fixed by glue or the like in a recess in the distal end of the tubing
of the catheter tip section. The arms comprise a backbone made of metal, e.g., Nitinol, of
semi-circular cross section. The metal backbones are completely or partially covered with an

1 insulation coating. One or more electrodes may be carried on the arms. In a preferred
embodiment suitable for ablation, the entire surface of the spline is uninsulated.

5 A particularly preferred basket assembly 12 is shown in Fig. 2. In this embodiment,
the outer surface of the middle half of the metal backbone of the arms (only two arms of five
are shown) are exposed to form electrodes 14. Additionally, each arm contains a ring-type
electrode 16 on the insulated portions of the arm both distally and proximally to the exposed
backbone portion. Preferred ring-type electrodes are formed by wrapping a lead wire around
the insulated coating a number of times and stripping the lead wire of its own insulated
coating on its outwardly facing surfaces. Such electrodes are disclosed for example in U.S.
10 Patent No. 5,772,590.

The particular construction of Figure 2 involving an electrode configuration of partially
exposed arms and adjacent wrapped electrodes is presently preferred because it has been found
to increase current density in a small area, allowing up to a 50% decrease in the current
needed to stimulate the nerve. This reduces the risk of tissue damage and other adverse
15 effects. In its expanded arrangement, the basket assembly is preferably no more than about
6 cm long and preferably from about 2 to about 4 cm long. Also in its expanded
arrangement, the diameter is adjustable to from about 10 to about 30 mm.

The catheter comprises a steering mechanism, for example, as described in U.S. Patent
No. RE 34,502 and U.S. Patent Application Nos. 09/157,055 (filed September 18, 1998),
20 09/130,359 (filed August 7, 1998), and 08/924,611 (filed September 5, 1997), which are
incorporated herein by reference. The steering mechanism comprises a puller wire (not
shown) which extends from a proximal end in the handle through the catheter body and into
an off axis lumen in the catheter tip section. Within the catheter body, the puller wire extends
through a closely wound coil that is bendable but substantially compressible. The coil is fixed
25 near the proximal and distal ends of the catheter body and prevents deflection of the catheter
body.

The distal end of the puller wire is anchored in the tip section adjacent the proximal
end of the basket. The proximal end of the puller wire is anchored to a movable member in
the handle which can be moved relative to the catheter body. Proximal movement of the
30 movable member relative to the catheter body. Proximal movement of the movable member
relative to the catheter body results in deflection of the catheter tip section.

A second puller wire 36 extends through the catheter body, catheter tip section and is
fixed to the distal fitting 44 of the basket. The second puller wire extends out of the proximal
end of the catheter and into the handle for applying a proximally directed force to the puller
35 wire. When the puller wire is moved proximally relative to the catheter body, the basket
expands outwardly. Outward expansion of the basket forces the arms against the vessel walls,
thereby impeding the motion of the arms relative to each other and resisting shifting of the
basket within the vessel. Such a second puller wire arrangement is disclosed, for example,

1 in U.S. Patent No. 5,772,590.

5 The handle 34 may be of any suitable construction for manipulating a pair of puller wires. Preferably the handle has a pair of movable members to which the puller wires attach. Manual movement of the movable members results in longitudinal movement of the puller wires relative to the catheter body. Manipulation of one puller wire provides deflection of the tip section. Manipulation of the second puller wire provides expansion or elongation of the basket. Preferred handles and steering mechanisms for the catheter are described in U.S. Patent Application No. 09/130,359 (filed August 7, 1998), and U.S. Provisional Patent Application No. 60/133,709 (filed May 12, 1999), which are also incorporated herein by reference.

10 It is understood that any suitable steering mechanism may be used. Alternatively, it is understood that the invention may be practiced without any steering mechanism and/or without the use of a puller wire mechanism for expanding or elongating the basket. As to the latter, the basket may be expanded and contracted, for example, by moving the guarding sheath proximally off of the basket or distally over the basket.

15 It is understood that any suitable catheter that can suitably maintain a stimulating electrode at an intravascular location adjacent a parasympathetic or sympathetic nerve can be used. Stable placement means that the electrode remains relatively immobile for the time period of stimulation, so that one or repeated stimuli are applied to the same area, and the nerve fibers receiving the stimuli receive approximately the same stimulus intensity from identical stimulation pulses. If such a catheter comprises a basket assembly, any suitable basket assembly may be used. That is, the number and type, e.g., semi-circular cross section, of arms may vary as desired. Likewise, the number and type of electrodes on the arms may vary. If desired, the metal backbones of the arms may be completely exposed or completely covered. The tip section may comprise a single lumen rather than the two described above or, in the alternative, may comprise three or more lumens. Likewise, the catheter body may comprise more than one lumen if desired.

25 If desired, a non-basket catheter may be used. If so, it is preferred that the catheter comprise some mechanism for anchoring the stimulating against the wall of the blood vessel it is in. Such mechanisms include extendable corkscrew anchors. Examples of suitable anchoring mechanisms are disclosed in U.S. Patent No. 5,431,168, which is incorporated herein by reference.

30 While it is presently preferred to use a guiding sheath, if the catheter comprises a mechanism for expanding and contracting the basket independent of the guiding sheath, a guiding sheath may not be required. This is particularly true if the catheter is steerable.

35 The catheter 10 is disposed within an outer guiding sheath 40 for placement at the desired intravascular location. The guiding sheath 40 covers the arms of the basket assembly internally in a collapsed position so that the entire assembly, consisting of the catheter 10 and

1 guiding sheath 40, can be passed down a vein or artery to a desired location. To reach the
desired intravascular location, the catheter and guiding sheath are inserted into a blood vessel
and then guided to the desired site. During this procedure, the tip may be deflected as needed
by manipulation of the first puller wire. Once the distal ends of the catheter 10 and guiding
5 sheath 40 reach the desired location, the guiding sheath 40 is withdrawn. The second puller
wire is then manipulated so that the arms of the basket assembly flex outwardly into their
expanded arrangement. In such an arrangement the arms and the electrodes contact the walls
of the blood vessel in which they are located.

10 Once the catheter basket is at the desired location, the controller 26 activates the signal
generator 18 to transmit signals sequentially to each of the electrodes on the basket and to
determine, based on signals received from the sensors 22 (indicating a response by the heart
to the transmitted signals) which of the electrodes is closest to the nerve. If there is no
response by the heart, the controller activates the signal generator to transmit a second signal
15 sequentially to each of the electrodes, said second signal being different from the first signal
in intensity, frequency or duration, preferably intensity. The controller continues this process
until a response by the heart is received and the electrode(s) closest to the nerve in question
is identified. If after a select period of time, if no response from the heart is sensed, the
controller provides a signal, e.g., audible or visual, to the physician indicating that the
20 electrode(s) are not sufficiently close to the desired nerve and that the catheter needs to be
repositioned.

Once the electrode(s) nearest the desired nerve has been identified, the controller
activates the pulse generator to transmit a stimulating signal to the identified electrode. If the
response by the heart is insufficient, e.g., not enough slowing, the controller activates the
pulse generator to vary the stimulating signal in one or more of the intensity, frequency and
25 pulse duration, preferably in a stepwise fashion, until the desired slowing of the heartbeat rate
is achieved. For example, a signal having an intensity sufficient to elicit a response from the
heart may slow the heartbeat rate to some degree but not as much as is desired. Accordingly,
the signal may be increased stepwise in intensity until the desired amount of slowing is
achieved.

30 The parasympathetic nervous system produces its cardiac action primarily via vagal
nerve fibers leading to cardiac ganglia. Sympathetic nerve fibers emerge from multiple
cervical and paravertebral ganglia to provide a network of postganglionic nerve endings to the
atria, ventricles, sinus node, and atrioventricular node. The terms "nerve" and "nerve fiber"
as used herein includes a single neuron, a nerve, nerve ending(s), or nerve bundle, and if it
35 is described as "autonomic," may be comprised of all parasympathetic, all sympathetic, or
mixed parasympathetic and sympathetic fibers.

Because of the pattern of cardiac autonomic innervation, the invention can be practiced
at numerous sites within the vasculature. In fact, any intravascular site which is adjacent to

1 an autonomic fiber that innervates the heart is a potential site for the stimulation method of
the invention. As used herein, "intravascular" means within the venous or arterial circulatory
system, including blood vessels of all descriptions and chambers of the heart. When referring
to "intravascular stimulation" in describing the method of the invention, it is meant stimulation
5 from within the circulatory system resulting in (transvascular) stimulation of a tissue of
interest. "Transvenous" or "transvascular" means across a blood vessel or across the wall of
a cardiac chamber (including the connective, adipose, muscle, neural, and other associated
tissue). "Stimulation" means a stimulus, usually electrical, which causes depolarization of a
cell or cells, or portion of a cell, contraction, excitation as measured by e.g., calcium or
10 sodium influx into the cell, or an altered membrane potential across a cell.

Appropriate sites for stimulation are those adjacent to cardiac autonomic nerves.
Preferably the sites are sufficiently far from myocardial muscle that the muscle is not at risk
of contraction during stimulation.

15 However, for some preferred sites, e.g., the coronary sinus, myocardial muscle is
adjacent and can be stimulated by the autonomic stimulation. This is rarely a problem when
the atria are in fibrillation, because the stimulation is incapable of causing coordinated atrial
contraction.

Potential stimulation sites can be initially selected by reference to general anatomy;
blood vessels of sufficient diameter for catheter access which are known to have autonomic
20 fibers innervating the heart running nearby or adjacent are suitable candidates. Care must be
taken, of course, to select locations with nerves that primarily innervate the area of interest
so that other innervated areas are not affected. For example, three preferred intravascular
parasympathetic sites at which a substantial reduction in ventricular rate during atrial
fibrillation can be obtained are the ostium of the coronary sinus, the right pulmonary artery
25 and the superior vena cava. Sympathetic bundles may be stimulated from discrete sites, for
example, transvascularly from the aorta or the main pulmonary artery to the sympathetic fibers
that run alongside. As will be apparent to one of skill in the art, the invention is not limited
to sites directly adjacent to the heart, but can be practiced at any of the variety of sites
(primarily thoracic) where blood vessels suitable for catheter access run parallel to or
30 otherwise intersect with autonomic fibers serving the heart. Target fibers can thus be accessed
from different sites on the patient, for example from near the subclavian, jugular, or azygous
veins.

In accordance with the method of the invention, the catheter is introduced into a blood
vessel and is guided by suitable means to a desired location. For example, fluoroscopic
35 imaging can be used to guide the catheter to the selected site. In addition or alternatively, if
the desired site is close to or within the myocardium, an electrode of the catheter may be used
to sense electrical activity of the heart, such that when signals generated by the contraction
of the cardiac muscle are detected, the sensing electrode is in the atrium. The catheter may

1 then be advanced through the heart or withdrawn to reach the desired site. If the target site
is just outside the heart, the catheter may be advanced or withdrawn until no myocardial
contraction is detected. For example, if the target is the right pulmonary artery, the catheter
would be advanced through the atrium, the tricuspid valve, and the right ventricle before
5 exiting the heart and entering the right pulmonary artery. When contraction of the heart is
no longer sensed, the catheter would be in a suitable position to begin testing for the desired
stimulation location. Likewise, if the target is the superior vena cava, for example, sensing
is performed from the catheter until atrial impulses are detected, indicating that the catheter
is in the atrium. From that point, the catheter is slowly withdrawn until atrial signals are no
10 longer detected. This would indicate that the catheter is in the superior vena cava.

Once a site is selected and the catheter is guided to the vicinity, accurate placement is
made by slowly advancing or withdrawing the catheter, expanding it to hold it in place, and
testing each electrode to identify the one closest to the selected nerve. If none of the arms
are suitably close to the nerve, the expanded basket is contracted and moved slightly to
15 another location. It is re-expanded and the electrodes re-tested. This process is repeated until
adequate nerve stimulation is achieved.

Stimulation can be optimized by varying the intensity, frequency, polarity, and/or pulse
duration of the signal. Of particular usefulness is changing the signal strength. A graded
response of the ventricular rate during atrial fibrillation ranging from slight slowing to
20 complete AV block can be accomplished. The desired level will be somewhere in between
these extremes, and will vary depending on the patient's condition. Parameters and protocols
for nerve stimulation can be any that produce the desired sympathetic or parasympathetic
effects on the heart, and can be adjusted as needed for different patients or during an
individual patient's treatment.

25 In general, stimulus pulse duration, amplitude, polarity, and/or intensity can be
modified. The pulse duration can be between about 1 microsecond to about 10 milliseconds,
preferably about 100 μ sec (0.1 ms); the frequency will be from about 1 to about 200 Hz,
preferably from about 20 - 45 Hz; and the stimulus intensity will be from about 1 to about
150 V, preferably from about 8 to about 15 V. The range of stimulation frequencies
30 possible, including the optimum range in the preparations tested is shown in Fig. 3.
Frequencies between about 20 and 45 Hz showed the most preferable supraventricular rate
slowing. The optimum signal will depend on the current density achieved at the stimulation
site, the voltage drop across the stimulating equipment to the delivery site, and other factors
well known to those of skill in the art. Lower voltages and frequencies are generally
35 preferred, since they reduce the risk of tissue damage or any possible discomfort in patients
arising from the stimulation. Shorter duration pulses are generally preferred because they
reduce the possibility of depolarizing nearby muscle fibers.

If the selected stimulation site is adjacent to cardiac muscle, contraction of the muscle

1 in response to the nerve stimulation can be avoided by timing the stimuli to coincide with the
myocardial refractory period (when no amount of stimulation will induce contraction of the
muscle). If this is done, a stronger signal may be used. If desired, concurrent pacing of the
atria or ventricles can be performed to time the nerve stimulation to the heartbeat or refractory
5 period of the muscle. Concurrent pacing can be performed with the same or a different
catheter or electrode(s), and can be within the heart or vasculature or externally using any
known methods. Likewise, recording or monitoring can be accomplished with the same or
different electrodes or catheters.

10 The system and methods of the invention can be used to ablate sympathetic and
parasympathetic nerves if necessary. Sympathectomy is indicated in certain patients, for
example those with contraindications to β -blockers. Selective sympathetic denervation,
performed by transvascular ablation using the method of the invention, can reduce these
patients' risk of sudden death from acute arrhythmias. Selective parasympathetic denervation
15 may be indicated in patients with atrial tachycardia or fibrillation induced or maintained by
excessive vagal nerve stimulation. A denaturing or ablating stimulus (e.g., radiofrequency
or cryoablation) is applied across the vessel wall to the sympathetic fibers at any desired
location. Preferably, sites are selected where a purely or nearly pure sympathetic or
parasympathetic branch runs very close to the vessel, and where there are few other nerves
20 or other sensitive tissues. Ablating stimulation is applied until conduction in the fiber is
impaired or ceases altogether. This can be monitored by any means, including recording from
the heart to observe a change in heart rate. Such ablation is irreversible, and can be very
selectively performed by first stimulating the nerve to determine its innervation sites and
selecting an ablation location that maximizes the desired effect while minimizing unwanted
ablation.

25 Example 1

Surgical Preparation and Parasympathetic Cardiac Nerve Stimulation and Measurement

Methods

30 All animal studies were carried out in accordance with the guidelines for animal care
and experimentation established by national agencies and were approved by the Research and
Development Committee of the Department of Veterans Affairs Medical Center, Oklahoma
City, Oklahoma. In 33 adult mongrel dogs (weight 18-30 kg) anesthesia was induced with
intravenous sodium pentobarbital (30 mg/kg body weight). During the experiment, 50 to 100
mg were injected as needed to maintain a sufficient depth of anesthesia. The dogs were
35 intubated with a cuffed endotracheal tube and ventilated with room air using a positive
pressure respirator (Harvard Apparatus Co., Natick, MA, USA). A cannula was inserted into
the left external jugular vein for fluid and drug delivery. Arterial blood pressure was
monitored through a cannula in the right femoral artery. A quadripolar catheter with 2 mm

1 interelectrode spacing was introduced into the left common carotid artery and advanced to the
aortic root to record His bundle activity as described elsewhere (14, herein incorporated by
reference). A right lateral thoracotomy was performed at the fourth intercostal space. After
pericardiotomy the right atrium and the right ventricle were exposed. Pairs of plunge wire
5 electrodes were inserted into the right atrial appendage and right ventricular apex for atrial and
ventricular pacing, respectively, and local electrogram recording. Surface ECG lead II and
aVR were monitored continuously. All tracings were amplified and digitally recorded using
a computer-based Bard Labsystem (CR Bard Inc., Billerica, MA, USA). ECG filter settings
were 0.01 to 250 Hz, whereas bipolar electrograms were filtered at 30 to 250 Hz.

10 A custom designed 7 French basket catheter, a preferred embodiment of the catheter
of the invention, was used for autonomic nerve stimulation (Cordis Webster Corp., CA). The
catheter used in the present study used each arm as the electrode ("multiple-spline catheter;"
portions of the arms were uninsulated). Bipolar electrical stimulation was done between
adjacent arms of the basket. Periods of electrical stimulation lasting 10 seconds were
15 delivered by means of a Grass stimulator (Astro-Med, Inc. / Grass Instruments Division, West
Warwick, RI) at a stimulation frequency of 20 Hz and a pulse duration of 0.05-0.1 ms. This
level of stimulation has previously been demonstrated to be suitable for epicardial
parasympathetic nerve fiber stimulation (10, herein incorporated by reference). Cardiac nerve
stimulation at each of three stimulation sites, i.e., the coronary sinus, the right pulmonary
20 artery, and the superior vena cava, was performed during atrial fibrillation. Atrial fibrillation
was induced and maintained by constant rapid pacing at a cycle length of 100 ms from the
electrodes in the right atrial appendage.

Group 1: Stimulation in the Coronary Sinus (n=10)

25 For parasympathetic stimulation in the coronary sinus, the catheter was introduced
through the right or left external jugular vein. It was then advanced into the right atrium under
fluoroscopic guidance. Positioning into the os of the coronary sinus was performed as
described previously (13, incorporated by reference). When the coronary sinus had been
entered, the basket was expanded to hold the catheter in a stable position against the
30 endovascular surface. Stimulation over each adjacent pair of electrode arms was then
attempted while the stimulus strength (SST) was increased stepwise from 7 to 50 V. If no
visible slowing of the ventricular rate during atrial fibrillation was observed, the basket was
contracted and the catheter gently rotated or advanced further into the coronary sinus until an
effective stimulation site was found.

35 Group 2: Stimulation in the Right Pulmonary Artery (n = 6)

For placement of the catheter in the right pulmonary artery the basket catheter was
introduced through a purse string suture in the right ventricular outflow tract. It was then

1 advanced under fluoroscopic control into the right pulmonary artery. Under fluoroscopy, the
basket was positioned between the aorta and the atrial channel between the superior vena cava
and inferior vena cava; however, electrode placement need not be done under fluoroscopic
conditions. The sinus rate slowing was then assessed by stimulation over each adjacent pair
5 of electrode arms at 40 V. If no visible ventricular rate slowing during atrial fibrillation
occurred, the basket was contracted and withdrawn stepwise. Stimulation was repeated until
a noticeable drop in ventricular rate during atrial fibrillation was achieved.

Group 3: Stimulation in the Superior Vena Cava (n = 6)

10 For stimulation in the superior vena cava, the catheter was introduced through the right
or left external jugular vein until a right atrial electrogram was recorded. The catheter was
then withdrawn to a site at which no atrial signal was recorded. At this point the basket was
expanded and the ventricular rate slowing effect during induced atrial fibrillation was assessed
by stimulation over each adjacent electrode pair at 40 V. If no slowing effect was observed,
15 the catheter was withdrawn and stimulation was repeated until a slowing response was
obtained. A successful intravascular stimulation site was located in the proximal right
pulmonary artery.

Once an effective coronary sinus, right pulmonary artery or superior vena cava site was
identified, neural stimulation was started at 2 V and thereafter stepwise increased to a
20 maximal voltage of 40 V. R-R intervals during cardiac nerve stimulation were measured in
surface ECG leads II and aVR. At each stimulus intensity, 10 consecutive R-R intervals after
the onset of cardiac nerve stimulation were measured for calculation of the mean R-R interval.

Measurement of Sinus Rate Slowing and Effective Refractory Period for Intravascular 25 Stimulation

In those dogs in which stimulation was performed at the superior vena cava and right
pulmonary artery sites, the atrial and ventricular effective refractory periods and AV
conduction during cardiac nerve stimulation were assessed. A-A intervals during
parasympathetic stimulation at 40 V were measured in the right atrial appendage electrogram.
30 The A-A intervals of 3 consecutive beats were taken for calculation of the mean A-A interval.
Right atrial and right ventricular ERPs were determined at baseline and during cardiac nerve
stimulation at the right pulmonary artery and superior vena cava sites by applying cardiac
parasympathetic stimulation at an intensity of 40 V. For atrial and ventricular pacing, 2 ms
rectangular pacing stimuli at twice the diastolic pacing threshold were delivered by a
35 Radionics stimulator (Radionics, Inc., Burlington, MA) at the right atrial and the right
ventricular pacing site using the extrastimulus technique. A train of 8 stimuli was delivered
at a cycle length of 400 ms followed by a premature stimulus starting with a coupling interval
of 350 ms. The premature stimulus was then decreased in 10 ms steps until no propagated

1 response was observed in the surface ECG or the local intracardiac electrogram. The longest coupling interval A_1-A_2 (V_1-V_2) of the premature beat that did not result in a propagated response was defined as the ERP at that stimulation site.

5 Long-term Stability of the Slowing Effect due to Parasympathetic Stimulation at the Coronary Sinus

Long-term efficacy of cardiac nerve stimulation at the coronary sinus site was also evaluated. For this purpose, in an additional dog, continuous parasympathetic stimulation was maintained at a stimulus strength of 25 V over 20.5 hours during pacing induced atrial
10 fibrillation. In this dog only, a left carotid arterial line and a right jugular access for introduction of the basket catheter were used. A thoracotomy was not performed. Every half hour the mean value of 10 consecutive R-R intervals during cardiac nerve stimulation was calculated. The stimulus voltage was then increased for 30 seconds to 39 V and another 10 consecutive R-R intervals were measured during this period. Both values were then compared
15 to 10 consecutive R-R intervals during a 30-second stimulation pause.

Pharmacological Tests and Cervical Vagal Nerve Cutting

In one dog of each of the three study groups, 2 mg of atropine were injected intravenously and parasympathetic stimulation was attempted again. In another dog of each
20 subgroup, both cervical vagal nerves were cut before parasympathetic stimulation was repeated. Also, in one dog of each study group, parasympathetic stimulation was repeated after topical application of 1% lidocaine on the outer surface of the proximal coronary sinus, close to the junction with the inferior vena cava.

25 Statistical Analysis

All data are expressed as mean \pm SD. In each group, repeated measure ANOVA was used to test whether the stimulus strength affected the ventricular rate during atrial fibrillation. The rate slowing effect at a given stimulus strength was compared to baseline values without parasympathetic stimulation applying a Wilcoxon matched pairs signed-rank test. In the dog
30 in which a 20.5-hour measurement was performed, rate differences were compared using a Wilcoxon matched pairs signed-rank test. Refractory periods were evaluated for significance by means of a Student paired t-test. Probability values < 0.05 were considered statistically significant.

Example 2

Results of Parasympathetic Cardiac Nerve Stimulation

A) Parasympathetic Cardiac Nerve Stimulation in the Coronary Sinus

Figure 4 shows a representative example of endovascular parasympathetic stimulation in the proximal coronary sinus. ECG leads II and aVR were recorded as well as an electrogram from the right atrial appendage. During parasympathetic stimulation with concomitantly induced atrial fibrillation, at 34 V and a frequency of 20 Hz, there was a marked increase of the R-R intervals (shortest 1440 ms, longest 1976 ms). Upon termination of parasympathetic stimulation (arrow), the longest and shortest R-R intervals were 600 and 260 ms, respectively. The lowest voltage at which at least a 50 % increase of the R-R interval occurred during atrial fibrillation was 18 ± 8 V (312 ± 102 ms without parasympathetic stimulation vs. 561 ± 172 ms during PS, $p < 0.001$). The effect of the applied stimulus voltage on the magnitude of ventricular rate slowing was assessed by a dose-response curve as illustrated in Figure 5. Stimulus strength significantly affected ventricular rate slowing during atrial fibrillation ($p < 0.001$, ANOVA). The graph also shows that direct extravascular stimulation of the parasympathetic ganglia at the proximal coronary sinus region yielded a much lower parasympathetic stimulation threshold. Importantly, nerve stimulation from the epicardium during sinus rhythm with a hand held bipolar electrode effectively prolonged the AH interval without a change in the sinus rate but was subthreshold for stimulation of atrial myocardial tissue. By contrast, if nerve stimulation from the intravascular site was performed during sinus rhythm, it excited the atria, resulting in atrial fibrillation except in a few instances.

B. Parasympathetic Cardiac Nerve Stimulation in the Right Pulmonary Artery

Stimulation in the right pulmonary artery also decreased the ventricular rate response during atrial fibrillation as depicted in Figure 6. During parasympathetic stimulation the largest R-R interval measured 3016 ms and the shortest 2008 ms whereas on termination of parasympathetic stimulation (arrow) the longest and shortest R-R intervals were 672 and 452 ms, respectively. The ventricular rate slowing effect depended on the stimulus strength ($p < 0.001$, ANOVA). Increasing the stimulus strength led to a graded response of ventricular rate slowing during atrial fibrillation as shown in Figure 6. The minimal stimulus strength inducing at least a 50 % prolongation of the R-R interval during atrial fibrillation required 23 ± 7 V (R-R interval of 307 ± 62 ms without parasympathetic stimulation vs. 681 ± 151 ms with parasympathetic stimulation, $p < 0.001$). Stimulation in the right pulmonary artery also produced a shortening of the average right atrial refractory period (136 ± 13 ms without parasympathetic stimulation vs. 96 ± 22 ms during parasympathetic stimulation $n = 5$, $p = 0.03$) whereas the right ventricular refractory period did not change significantly with neural stimulation (184 ± 25 ms with parasympathetic stimulation vs. 186 ± 26 without

1 parasympathetic stimulation, $n=5$). Moreover, a significant slowing of sinus rate was observed during stimulation at the right pulmonary artery site (1181 ± 306 ms during parasympathetic stimulation vs. 518 ± 138 ms without parasympathetic stimulation, $n = 6$, $p = 0.01$).

5 C. Parasympathetic Cardiac Nerve Stimulation in the Superior Vena Cava

A sufficient ventricular rate slowing during atrial fibrillation was also observed during parasympathetic stimulation in the proximal SVC. A typical example is shown in Figure 8A. At the onset of parasympathetic stimulation (arrow, stimulus strength of 13 V) the longest and shortest R-R intervals measured were 1464 and 384 ms, respectively, compared to baseline values of 408 and 352 ms. During parasympathetic stimulation at a stimulus strength of 22 V (arrow, FIG. 8B), these values increased to 2336 and 1008 ms. The lowest voltage at which a 50% increase of the mean ventricular cycle length during atrial fibrillation occurred was 25 ± 11 V (331 ± 139 ms without parasympathetic stimulation vs. 653 ± 286 ms during parasympathetic stimulation, $p < 0.001$). The stimulus strength during parasympathetic stimulation significantly affected the ventricular rate during atrial fibrillation as illustrated by Figure 9 ($p < 0.001$, ANOVA). During sinus rhythm, maximal cardiac nerve stimulation led to a significant increase in the average sinus cycle length (489 ± 154 ms without parasympathetic stimulation vs. 1056 ± 355 ms with PS, $n = 6$, $p < 0.001$) and to a shortening of the right atrial refractory period (145 ± 55 ms without parasympathetic stimulation vs. 78 ± 71 ms with PS, $n = 6$, $p = 0.03$). The right ventricular refractory period did not change significantly during parasympathetic stimulation (172 ± 26 ms with parasympathetic stimulation vs. 176 ± 34 ms without parasympathetic stimulation, $n = 5$). Intermittent stimulation of the phrenic nerve was sometimes observed during stimulation across various splines of the electrode basket catheter. When the site and electrode pair was found at which electrical stimulation induced ventricular slowing during atrial fibrillation, stimulation of the phrenic nerve was never observed.

25 D. Effect of Different Nerve Stimulation Algorithms

30 Stimulation in the coronary sinus during sinus rhythm in most instances resulted in local atrial tissue capture, thereby inducing atrial fibrillation at a voltage that was lower than the one which resulted in ventricular rate slowing during atrial fibrillation. However, stimulation in the right pulmonary artery or superior vena cava did not capture any myocardial tissue.

35 Therefore, another algorithm for parasympathetic stimulation at the coronary sinus site was tested: trains of stimuli (stimulus frequency: 200 Hz) each lasting 10 ms were delivered at a train rate of 200/min (cycle length = 300 ms). These pulsed trains also excited atrial tissue, resulting in atrial pacing at a rate of 200/min. Importantly, 2:1 AV block was observed during these episodes. Without pulsed parasympathetic stimulation but with pacing from the

1 right atrial appendage site at a rate of 200/min, no AV block was present.

5 The efficacy of intermittent stimulation trains to slow the ventricular rate during atrial fibrillation is illustrated in Figure 10. At a stimulus strength of 34 V, intermittent pulses of parasympathetic stimulation (constant train cycle length of 300 ms, train duration 10 ms) markedly reduced the ventricular response during atrial fibrillation. A negative dromotropic effect was also achieved when the trains of stimuli were delivered irregularly as demonstrated in Figure 10B. At the beginning of the recordings trains with frequent pulsing but irregular train cycle length resulted in a notable ventricular cycle length prolongation (1900 ms longest, 630 ms shortest) during atrial fibrillation. When the pulsing was infrequent and irregular (right side of the tracings), the ventricular cycle length prolongation during atrial fibrillation was not as great (600 ms longest, 265 ms shortest).

10 Increasing the train cycle length from 300 ms to 500 ms at a train duration of 10 ms led to a decrease of the ventricular rate slowing effect during parasympathetic stimulation at 34 V (average ventricular cycle length of 2105 ± 1160 ms at a train cycle length of 300 ms vs. 942 ± 294 ms at a train cycle length of 500 ms vs. 379 ± 65 ms without parasympathetic stimulation, $n = 2$). The rate slowing effect also depended on the train duration as found in another 2 dogs: at a constant train cycle length of 300 ms, the decrease in average ventricular cycle length during atrial fibrillation was higher for trains lasting 100 ms 13 (1325 ± 663 ms, SST; 150 V) than for trains with a duration of 10 ms (1156 ± 566 ms, SST: 150 V vs. 474 ± 91 ms without parasympathetic stimulation, $n = 2$).

E. Long-term Stability of the Slowing Effect due to Parasympathetic Stimulation at the Coronary Sinus

25 To test if there was a fading of the slowing effect during a longer stimulation period, continuous nerve stimulation in the coronary sinus was performed over 2 hours in 2 dogs. Although the mean R-R interval during atrial fibrillation after 2 hours of parasympathetic stimulation was shorter than at the onset of parasympathetic stimulation (644 ± 149 ms vs. 778 ± 210 ms, $n = 2$), it was still longer compared to the R-R intervals without parasympathetic stimulation (452 ± 114 ms, $n = 2$). In another dog, the stability of the rate slowing effect was assessed over a 20.5-hour period as illustrated in Figure 11. The effect of ventricular rate slowing during atrial fibrillation slightly decreased over the 20.5-hour period of parasympathetic stimulation. However, after 20.5 hours there was still a considerable decrease of the ventricular rate during parasympathetic stimulation as compared to no parasympathetic stimulation. The latter was determined during a 30 s period of no parasympathetic stimulation. 30 Of note, this small loss of efficacy over 20.5 hours was overcome if the stimulus strength was increased from 36 V to 39 V as shown in Figure 11.

F. Pharmacological Procedures and Cutting of the Cervical Vagal Nerves

1 At all three stimulation sites, the effect of parasympathetic stimulation on the
ventricular response during atrial fibrillation was completely abolished after intravenous
injection of 2 mg of atropine. Similarly, local extravascular application of lidocaine (to block
5 nerve conduction) on the proximal coronary sinus close to the junction of the inferior vena
cava and right atrium prevented the ventricular rate slowing effect during parasympathetic
stimulation in the right pulmonary artery, superior vena cava and coronary sinus. By contrast,
cutting both cervical vagal nerves did not change the parasympathetic stimulation related
decrease of the ventricular response during atrial fibrillation at any of the 3 stimulation sites.

10 G. Comparison of Various Sites for Parasympathetic Stimulation

Although a sufficient ventricular rate reduction was consistently achieved at each
stimulation site, there are specific characteristics of each location which may influence the
choice of sites for use in individual patients. Placement of an electrode catheter without a
deflectable tip in the coronary sinus through jugular or subclavian venous access is a standard
15 procedure during electrophysiological procedures in patients. Similarly, introduction of the
basket catheter in the coronary sinus was achieved by a transvenous access in our study.
However, because this approach may require some technical experience, entrance to the right
pulmonary artery may be more readily achieved in individual patients. This is because most
physicians may be more confident doing pulmonary catheterization, which is a standard
20 procedure during evaluation of valvular or congestive heart disease, than coronary sinus
catheterization. However, both the coronary sinus and the right pulmonary artery approach can
be used with a fluoroscopy to position the catheter. On the other hand, the superior vena cava
site was reached without fluoroscopy in the Examples, making this approach more suitable
for an acute emergency situation in critically ill patients.

25 A limitation of continuous stimulation at the coronary sinus site is that effective
parasympathetic stimulation may result in electrical excitation of atrial tissue. Although this
is not relevant in the setting of chronic atrial fibrillation, it may contribute to the perpetuation
of atrial fibrillation in patients with recent onset atrial fibrillation. An algorithm consisting of
repetitive trains of stimuli has proved to be efficacious in slowing the heart rate during atrial
30 fibrillation. The negative dromotropic effects were higher with more frequent or longer
duration trains. Therefore, one can couple trains of stimuli to the QRS complex during atrial
fibrillation to result in an automatic adjustment of the intensity of parasympathetic stimulation
to the ventricular rate during atrial fibrillation. Moreover, in case of termination of atrial
fibrillation, ongoing train delivery may only evoke atrial extrasystoles that are coupled to the
35 QRS complex and may not reinduce atrial fibrillation.

Once the catheter was positioned at any of the three stimulation sites and the basket
was expanded, no dislocation of the catheter was observed. Theoretically, in case of
dislocation of the stimulating catheter in the coronary sinus or right pulmonary artery catheter

1 in the right ventricle, induction of ventricular fibrillation might occur if a continuous
stimulation algorithm is applied. This may be avoided by delivering trains of parasympathetic
stimuli during the absolute ventricular refractory period which could be achieved by triggered
5 delivery of the trains immediately after the end of the QRS complex.

Example 3: Ablation of Parasympathetic Nerves

A. Ablation at the Junction of the Superior Vena Cava and Right Atrium Terminates Neurally Induced Atrial Fibrillation.

10 Atrial tissue at the junction of the superior vena cava (SVC) and right atrium (RA) has
been implicated as the source for symptomatic atrial tachycardia and atrial fibrillation. Here,
eight dogs were anesthetized with sodium pentobarbital, and had a basket catheter of the
invention expanded at the SVC/RA junction for bipolar recording and pacing. Atrial
electrograms were also recorded from close bipolar electrodes at the right atrium and left atrial
15 appendage, along Bachmann's bundle, coronary sinus and the pulmonary veins. In order to
avoid atrial activation during nerve stimulation, the right atrium was paced at a rate of either
150/min or 330/min with each pacing stimulus coupled (20 msec) to a 50 msec train of high
frequency stimuli (200 Hz, each stimulus lasting 0.1 msec). Voltages for neural stimulation
trains were titrated from 2-40 V.

20 At an average of 23 ± 4 V (mean \pm std. dev.), rapid atrial tachycardia leading to atrial
fibrillation was induced which was characterized by early activation and continuous electrical
activity in the vicinity of the SVC. At significantly lower voltages (17 ± 6 V, $p=0.02$),
concealed atrial ectopic beats were recorded with occasional firing from the SVC area
showing exit block to the rest of the atria. With beta-blockade (esmolol, 1mg/kg, $n=4$), the
25 atrial fibrillation threshold increased to 28 ± 6 V ($n=3$, $p=0.04$). In one dog, atrial fibrillation
was no longer inducible after esmolol injection. Atropine (2mg, $n=3$) completely abolished
stimulation induced atrial premature beats, atrial tachycardia, and atrial fibrillation. Two to
four hours after autonomic blockade, the stimulation induced arrhythmias returned.
Radiofrequency current (70V, impedance 180-220 ohms, 60 sec, $n=8$) again completely
30 abolished the induction of atrial premature beats, atrial tachycardia and atrial fibrillation, even
at the highest voltage (39 V). The average number of radiofrequency current ablations needed
to achieve these results was 2.9 ± 1.6 / dog.

35 The SVC/RA junction appears to be a site for neurally induced atrial premature beats,
atrial tachycardia and atrial fibrillation which can be abolished by autonomic blockade or
electrical ablation of parasympathetic atrial innervation. Ablation may destroy the atrial
myocardium which is the source of the arrhythmias or the adjacent neural elements or both.

1 B. Ablation at the Inferior Vena Cava and Right Pulmonary Artery Abolishes Vagal Atrial
5 Fibrillation

The parasympathetic nervous system considerably shortens the atrial refractory period and can maintain atrial fibrillation. We demonstrated that intravascular radiofrequency catheter ablation of the parasympathetic nerves innervation the atria can be achieved and prevents electrically induced atrial fibrillation which was maintained by supramaximal bilateral cervical vagal nerve stimulation (VNS).

10 In six dogs, intravascular atrial denervation (IAD) was performed using intravascular radiofrequency current ablation of parasympathetic atrial nerves in the right pulmonary artery and inferior vena cava. Atrial fibrillation was induced with rapid atrial stimulation and maintained by VNS. Before and after IAD, the product of conduction velocity and atrial refractory period (AERP) was determined at seven atrial sites (high and low right atrium, proximal and distal coronary sinus and Bachmann bundle, left superior pulmonary vein) at baseline and during VNS. Before IAD, AERPs shortened from 124 ± 5 ms at baseline to 40 ± 7 ms during VNS ($p < 0.001$). At all seven atrial sites, atrial fibrillation could be induced and maintained by rapid atrial stimulation and VNS. After IAD, vagally induced shortening of the AERPs was considerably blunted (125 ± 3 ms at baseline to 116 ± 5 ms during VNS, $p = 0.01$). After IAD, atrial fibrillation could not longer be induced and maintained by rapid atrial stimulation and VNS at any of the seven atrial sites. No intravascular thrombi or vessel perforation were observed after ablation.

20 The description and Examples herein show for the first time a transvenous approach to stable and consistent acute and long term parasympathetic cardiac nerve stimulation. Using the stimulation method and catheter of the invention, it has been shown that the negative dromotropic effect during intravascular coronary sinus stimulation is sufficient to cause a considerable ventricular rate slowing during atrial fibrillation. The use of the basket catheter allows rapid, consistent, and stable electrode placement at the desired site, even over long time periods. A negative dromotropic effect can also be achieved during intravascular stimulation in the superior vena cava or right pulmonary artery. In addition to a negative dromotropic effect, a negative chronotropic effect and a shortening of the atrial refractory period can be achieved in the superior vena cava and right pulmonary artery.

30 The system and method of the invention provide means to stimulate autonomic neurons innervating the heart from within the vasculature to regulate atrial and/or ventricular function. Beneficial results are achieved by significant supraventricular and ventricular rate slowing. Such treatment is particularly useful to counteract undesirable positive chronotropic effects of catecholamines during treatment of cardiogenic or septic shock, acute congestive heart failure, or in patients with rapid ventricular response during atrial fibrillation and poor left ventricular function who are not good candidates for beta blockers or calcium channel antagonists. Additionally, autonomic nerve stimulation or selective ablation is useful in

1 patients with conditions such as paroxysmal atrial fibrillation and symptomatic atrial
tachycardia and fibrillation. The disclosed methods are superior to previously reported
stimulation methods to correct tachycardia because they do not require surgical entry into the
thoracic cavity, and do not require ablation of muscle.

5 The preceding description has been presented with references to presently preferred
embodiments of the invention. Persons skilled in the art and technology to which this
invention pertains will appreciate that alterations and changes in the described structures and
methods can be practiced without meaningfully departing from the principle, spirit and scope
of this invention.

10 Accordingly, the foregoing description should not be read as pertaining only to the
precise structures and methods described and shown in the accompanying drawings, but rather
should be read as consistent with and as support for the following claims, which are to have
their fullest and fairest scope.

15 References

1. Prystowsky EN, Benson DW, Fuster V, Hart RG, Neal Kay GN, Myerburg RJ, Naccarelli GV, Wyse DG. Management of patients with atrial fibrillation: A statement for healthcare professionals from the subcommittee on electrocardiography and electrophysiology, American Heart Association. *Circulation* 1996;93:1262-1277
- 20 2. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. *Stroke* 1991 ;22:983-988
3. Kannel WB, Abbott RD, Savage DD, McNamara PM. Epidemiologic features of chronic atrial fibrillation: The Framingham Study. *N Engl J Med* 1982; 306:1018-22
- 25 4. Benjamin EJ, Levy D, Vazir SM et al. Independent risk factors for atrial fibrillation in a population-based cohort. *JAMA* 1994;271:840-844
5. Van Gelder IC, Crijns HJ. Cardioversion of atrial fibrillation and subsequent maintenance of sinus rhythm. *Pacing Clin Electrophysiol* 1997; 20 (10,2): 2675-2683
6. Brodsky MA, Allen B J, Walker CJ, et al. Amiodarone for maintenance of sinus rhythm after conversion of atrial fibrillation in the setting of dilated left atrium. *Am J Cardiol* 1987;60:572-575
- 30 7. Myerburg RJ, Castellanos A. Cardiac arrest and sudden death. In: Braunwald E, ed. *Heart disease: A textbook of cardiovascular medicine*, 4th edition, Philadelphia, WB Saunders 1992:756-789.
- 35 8. Vanoli E, De Ferrari GM, Stramba-Badiale M et al. Vagal stimulation and prevention of sudden death in conscious dogs with a healed myocardial infarction. *Circ Res* 1991;68:1008-1014.
9. Puddu PE, Jouve R, Langlet F et al. Prevention of postischemic ventricular fibrillation

- 1 late after right or left stellate ganglionectomy in dogs. Circulation 1988;77:935-946.
10. Lazzara R, Scherlag BJ, Robinson MJ et al. Selective *in situ* parasympathetic control
of the canine sinuatrial and atrioventricular node. Circ Res 1973; 32:393-401
11. Chen SA, Chiang CE, Tai CT et al. Intracardiac stimulation of human parasympathetic
5 nerve fibers induces negative dromotropic effects: implication with the lesions of
radiofrequency catheter ablation. Cardiovasc Electrophysiol. 1998;9: 245-252
12. Reek S, Geller JC, Hartung WM, Auricchio A. Einfluss transvenöser elektrischer
Stimulation in der rechten Pulmonalarterie auf Sinusknotenläre und ventrikuläre
Refraktärzeiten. Z Kardiologie 1999;88, Suppl 1:10
- 10 13. Murphy DA, Johnstone DE, Armour JA. Preliminary observations on the effects of
stimulation of cardiac nerves in man. Can J Physiol Pharmacol. 1985;63:649-655
14. Quan KJ, Mackall JA, Biblo LA, Van Hare GF, Carlson MD. Endocardial
parasympathic stimulation slows the ventricular rate during atrial fibrillation in humans.
PACE 1996;19:647 (abstract)
- 15 15. Chiou CW, Eble JN, Zipes DP. Efferent vagal innervation of the canine atria and sinus
and atrioventricular nodes. Circulation 1997;95:2573-2584
16. Thompson GW, Levett JM, Miller SM et al. Bradycardia induced by intravascular
versus direct stimulation of the vagus nerve. Ann Thorac Surg 1998;65(3):637-42
17. Coumel P et al. Syndrome d'arythmie auriculaire d'origine vagale. Arch Mal Coeur
20 1978;71:645-656.
- 25
- 30
- 35

1 CLAIMS

1. A method of regulating the heart rate of a patient comprising:
inserting an electrophysiology catheter having a tip section with at least one stimulating
5 electrode into a blood vessel and directing the catheter to an intravascular location wherein
the at least one stimulating electrode of the catheter is adjacent a selected cardiac sympathetic
or parasympathetic nerve;
stabilizing the at least one electrode at said intravascular location; and
delivering a stimulus through the at least one electrode, said stimulus selected to
10 stimulate the adjacent sympathetic or parasympathetic nerve to thereby cause a regulation of
the patient's heart rate.
2. The method of claim 1 wherein the stimulation causes a slowing of the heart
rate.
- 15 3. The method of claim 2 wherein the patient is suffering from atrial or ventricular
tachycardia.
4. The method of claim 2 wherein the patient is suffering from atrial flutter.
- 20 5. The method of claim 2 wherein the patient is suffering from atrial fibrillation.
6. The method of claim 1 wherein the intravascular location is selected from the
group consisting of coronary sinus, right pulmonary artery, and superior vena cava.
- 25 7. The method of claim 1 wherein the catheter is steerable.
8. A method as claimed in claim 1 wherein the catheter comprises
an elongated catheter body having proximal and distal ends and at least one lumen
30 therethrough;
a tip section comprising a section of flexible tubing having proximal and distal ends
and at least one lumen therethrough, the proximal end of said tubing being fixedly attached
to the distal end of the catheter body, said tip section further comprising a basket assembly
at the distal end of the flexible tubing, said basket assembly comprising a plurality of arms
35 connected at their proximal and distal ends, each arm comprising at least one electrode, said
basket assembly having an expanded arrangement wherein the arms bow radially outwardly
and a collapsed arrangement wherein the arms are arranged generally along the axis of the
catheter tip section; and

1 wherein at least one arm comprises the at least one stimulating electrode.

5 9. A method as claimed in claim 8 wherein the at least one stimulating electrode is stabilized at said intravascular location by expanding the basket assembly at that intravascular location.

10 10. The method of claim 9 wherein the diameter of the basket assembly in its expanded arrangement is no more than about 30 mm and the length of the basket assembly in its expanded arrangement is no more than about 60 mm.

11. A method as claimed in claim 9 wherein the length of the basket assembly in its expanded arrangement is from about 20 to about 40 mm.

15 12. A method as claimed in claim 11 wherein the diameter of the basket assembly in its expanded arrangement is from about 10 mm to about 15 mm.

20 13. The method of claim 1 wherein the stimulus comprises one or more electrical signals having a frequency of from about 1 Hz to about 200 Hz, an intensity of from about 1V to about 150V and a duration of from about 0.01 msec to about 10 msec.

14. The method of claim 13 wherein the frequency of the electrical signal(s) is between about 20 Hz to about 30 Hz.

25 15. The method of claim 13 wherein the intensity of the electrical signal(s) is from about 8V to about 15V.

16. The method of claim 13 wherein the duration of the electrical signal(s) is from about 0.05 msec to about 0.1 msec.

30 17. The method of claim 1 wherein the stimulation is timed to occur during a myocardial refractory period.

35 18. The method of claim 17 wherein the refractory period is regulated by myocardial pacing.

19. The method of claim 18 wherein the myocardial pacing is elicited from the stimulating electrode or a second electrode on the catheter.

- 1 20. The method of claim 1 wherein the nerve is primarily parasympathetic.
21. The method of claim 1 wherein the nerve is primarily sympathetic.
- 5 22. A method of regulating the heart rate of a patient comprising:
 providing an electrophysiological catheter comprising:
 an elongated catheter body having proximal and distal ends and at least one
 lumen therethrough;
 a tip section comprising a section of flexible tubing having proximal and distal
10 ends and at least one lumen therethrough, the proximal end of said tubing being fixedly
 attached to the distal end of the catheter body, said tip section further comprising a basket
 assembly at the distal end of the flexible tubing, said basket assembly comprising a plurality
 of arms connected at their proximal and distal ends, each arm comprising at least one
 electrode, said basket assembly having an expanded arrangement wherein the arms bow
15 radially outwardly and a collapsed arrangement wherein the arms are arranged generally along
 the axis of the catheter tip section;
 inserting the catheter into a blood vessel and directing the catheter to an intravascular
 location, wherein the at least one electrode of basket assembly is adjacent a selected cardiac
 sympathetic or parasympathetic nerve;
20 expanding the basket assembly to stabilize the at least one electrode adjacent the
 selected cardiac sympathetic or parasympathetic nerve; and
 delivering a stimulus through the at least one adjacent electrode, said stimulus selected
 to stimulate the adjacent sympathetic or parasympathetic nerve to thereby cause a regulation
 of the patient's heart rate.
- 25 23. The method of claim 22 wherein the stimulation causes a slowing of the heart
 rate.
24. The method of claim 23 wherein the patient is suffering from atrial or ventricular
30 tachycardia.
25. The method of claim 22 wherein the patient is suffering from atrial flutter.
26. The method of claim 22 wherein the patient is suffering from atrial fibrillation.
- 35 27. The method of claim 22 wherein the intravascular location is selected from the
 group consisting of coronary sinus, right pulmonary artery, and superior vena cava.

1 28. The method of claim 1 wherein the catheter is steerable.

5 29. The method of claim 22 wherein the diameter of the basket assembly in its expanded arrangement is no more than about 30 mm and the length of the basket assembly in its expanded arrangement is no more than about 60 mm.

 30. The method of claim 29 wherein the length of the basket assembly in its expanded arrangement is from about 20 to about 40 mm.

10 31. A method as claimed in claim 30 wherein the diameter of the basket assembly in its expanded arrangement is from about 15 mm to about 28 mm.

 32. The method of claim 22 wherein the stimulus comprises one or more electrical signals having a frequency of from about 1 Hz to about 200 Hz, an intensity of from about 1V to about 200 V and a duration of from about 0.01 msec to about 10 msec.

 33. The method of claim 32 wherein the frequency of the electrical signal(s) is about 20 Hz to about 30 Hz.

20 34. The method of claim 32 wherein the intensity of the electrical signal(s) is from about 8V to about 15V.

 35. The method of claim 32 wherein the duration of the electrical signal(s) is about 0.05 msec to about 0.1 msec.

25 36. The method of claim 22 wherein the stimulation is timed to occur during a myocardial refractory period.

30 37. The method of claim 38 wherein the refractory period is regulated by myocardial pacing.

 38. The method of claim 37 wherein the myocardial pacing is elicited from the stimulating electrode or a second electrode on the catheter.

35 39. The method of claim 22 wherein the nerve is primarily parasympathetic.

 40. The method of claim 22 wherein the nerve is primarily sympathetic.

1 41. A method of selectively ablating a sympathetic or parasympathetic innervation
of at least one portion of the heart of a patient comprising:
 inserting an electrophysiological catheter having a tip section with an ablation electrode
into a blood vessel and directing the catheter to an intravascular location wherein the ablation
5 electrode of the catheter is adjacent to a selected sympathetic or parasympathetic nerve;
 stabilizing the ablation electrode at said intravascular location;
 delivering an ablation stimulus through the electrode, said ablating stimulus being
sufficient to damage the nerve so that it no longer conducts impulses to the heart.

10 42. The method of claim 41 wherein the ablating stimulus comprises a
radiofrequency stimulus.

 43. The method of claim 41 wherein the ablating stimulus comprises a cryoablation
stimulus.

15 44. A system to regulate the heart rate of a patient comprising:
 a) a catheter having:
 an elongated catheter body, the body having proximal and distal ends and at least one
lumen therethrough;
20 a tip section comprising a section of flexible tubing having proximal and distal ends
and at least one lumen therethrough, the proximal end of said tubing being fixedly attached
to the distal end of the catheter body, said tip section further comprising a basket assembly
at the distal end of the flexible tubing, said basket assembly comprising a plurality of arms
connected at their proximal and distal ends, each arm comprising at least one electrode, said
25 basket assembly having an expanded arrangement wherein the arms bow radially outwardly
and a collapsed arrangement wherein the arms are arranged generally along the axis of the
catheter tip section, the length of the basket assembly in its expanded arrangement being from
about 20 to about 60 mm; and
 b) a pulse generator electrically connected to the at least one electrode in each arm
30 of the basket assembly, said pulse generator capable of generating stimulating pulses having
a frequency of from about 1 Hz to about 200 Hz, an intensity of from about 1V to about
200 V and a duration of from about 0.01 msec to about 10 msec.

35 45. The system of claim 44 wherein the length of basket assembly in its expanded
arrangement is from about 20 to about 40 mm.

 46. The system of claim 44 wherein the diameter of the basket assembly in its
expanded arrangement is from about 10 to about 30 mm.

1 47. The system of claim 45 wherein the diameter of the basket assembly in its expanded arrangement is from about 10 to about 20 mm.

5 48. The system of claim 44 wherein the frequency of the stimulating pulses is between about 20 Hz to about 30 Hz, the intensity of the electrical signal(s) is between about 8V to about 15V, and the duration of the electrical signal(s) is from about 0.05 msec to about 0.1 msec.

10 49. The system of claim 44 further comprising a heart rate monitor for monitoring the heart rate of a patient.

 50. The system of claim 49 further comprising a display for displaying the monitored heart rate of a patient.

15 51. The system of claim 49 further comprising a programmable controller electrically connected to the pulse generator and to the heart rate monitor, said controller programmed to activate the pulse generator to transmit a select stimulating pulse sequentially to each of the at least one electrode of each basket assembly arm after the catheter has been inserted into a blood vessel of a patient and placed at an intravascular location adjacent a sympathetic or
20 parasympathetic nerve to be stimulated and for determining which of the at least one electrodes are closest to the nerve to be stimulated.

 52. The system of claim 51 wherein the controller is further programmed to, once the at least one electrode nearest the nerve to be stimulated has been determined, activate the
25 pulse generator to transmit a stimulating signal to said nearest at least one electrode and to vary one or more of the intensity, frequency, and pulse duration of said stimulating signal to obtain a select reduction in the heart beat rate of the patient.

30 53. A catheter for use in regulating the heart rate of a patient comprising:
 an elongated catheter body, the body having proximal and distal ends and at least one lumen therethrough;

 a tip section comprising a section of flexible tubing having proximal and distal ends and at least two lumens therethrough, at least one such lumen being off-axis, the proximal end of said tubing being fixedly attached to the distal end of the catheter body, said tip section
35 further comprising a basket assembly at the distal end of the flexible tubing, said basket assembly comprising a plurality of arms connected at their proximal ends by a proximal fitting and at their distal ends by a distal fitting, each arm comprising at least one electrode, said basket assembly having an expanded arrangement wherein the arms bow radially outwardly

1 and a collapsed arrangement wherein the arms are generally straight and are arranged generally along the axis of the catheter tip section; the length of the basket assembly in its expanded arrangement being from about 20 mm to about 60 mm and the diameter of the basket assembly in its expanded arrangement being from about 10 mm to about 30 mm;

5 a control handle at the proximal end of the catheter body, said control handle having first and second movable members, each being movable between first and second positions;

a first puller wire comprising a proximal end attached to the first movable member of the handle, and extending through the catheter body and into an off-axis lumen in the tip section, the distal end of the first puller wire being anchored to the tip section so that
10 movement of the first movable member from a first to a second position results in longitudinal movement of the first puller wire relative to the catheter body and deflection of the tip section.

a second puller wire comprising a proximal end attached to the second movable member of the handle and extending through a lumen in the catheter body and a lumen of the tip section and the proximal fitting, the distal end of the second puller wire being attached to the distal fitting of the basket assembly such that movement of the second movable member from a first to a second position results in longitudinal movement of the second puller wire relative to the catheter body and expansion of the basket assembly; and

20 a plurality of electrode lead wires extending through the handle and catheter body, each lead wire attached to a corresponding electrode of the basket assembly.

54. The catheter of claim 53 wherein the length of the basket assembly in its expanded arrangement is from about 20 to about 30 mm.

25 55. The catheter of claim 53 wherein the diameter of the basket assembly in its expanded arrangement is from about 10 to about 30 mm.

56. The catheter of claim 53 wherein each arm of the basket assembly comprises a metal backbone, at least a portion of which forms an electrode.

30 57. The catheter of claim 56 wherein the metal backbone of each arm comprises an insulating coating covering at least a portion of the metal backbone.

58. The catheter of claim 57 wherein a middle portion of the metal backbone of each
35 arm is exposed and forms an electrode.

59. The catheter of claim 58 wherein each arm comprises an electrode distal to the exposed portion of the metal backbone.

1 60. The catheter of claim 58 wherein each arm comprises an electrode proximal to
the exposed portion of the metal backbone.

5 61. The catheter of claim 58 wherein each arm comprises electrodes proximal and
distal to the exposed portion of the metal backbone.

10


15



20

25


30

35





3/11

Fig. 3





Fig. 4

5/11



6/11





Fig. 6

7/11



8/11

Fig. 8A




Fig. 8B





Fig. 8

9/11



10/11

Fig. 10A

A. REGULAR PULSING - 34 VOLTS (PULSE CL=300MS, DURATION=10MS)

1/SEC





Fig. 10B

B. IRREGULAR PULSING - 34 VOLTS (PULSE DURATION=10MS)



11/11




Fig. 11

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/13719

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :A61N 1/05

US CL :607/9

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 600/374, 375, 381; 607/9, 14, 98, 99, 101, 113, 122, 126

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5,411,531 A (HILL et al.) 02 May 1995, entire document.	1-7, 13-21, 28
A	US 5,466,245 A (SPINELLI et al.) 14 November 1995, entire document.	1-61
A	US 5,700,282 A (ZABARA) 23 December 1997, entire document.	1-61
A, P	US 5,876,336 A (SWANSON et al.) 02 March 1999, entire document.	8-12, 22, 29-31, 41-47, 49-61

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

A	Special categories of cited documents: document defining the general state of the art which is not considered to be of particular relevance	*T*	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
E	earlier document published on or after the international filing date	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
L	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
O	document referring to an oral disclosure, use, exhibition or other means	*Z*	document member of the same patent family
P	document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

12 SEPTEMBER 1999

Date of mailing of the international search report

21 OCT 1999

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

KENNEDY SCHAETZLE

Telephone No. (703) 308-2211

Form PCT/ISA/210 (second sheet)(July 1992)*

